- Mesothelioma news are updated once a hour
- We deliver news from more than 500 sources on mesothelioma
NewsAdvertisers: |
An insult to the bereaved...
Timeout expired. The timeout period elapsed prior to completion of the operation or the server is not responding. body {font-family:"Verdana";font-weight:normal;font-size: .7em;color:black;} p {font-family:"Verdana";font-weight:normal;color:black;margin-top: -5px} b {font-family:"Verdana";font-weight:bold;color:black;margin-top: -5px} H1 { font-family:"Verdana";font-weight:normal;font-size:18pt;color:red } H2 { font-family:"Verdana";font-weight:normal;font-size:14pt;color:maroon } pre {font-family:"Lucida Console";font-size: .9em} .marker {font-weight: bold; color: black;text-decoration: none;} .version {color: gray;} .error {margin-bottom: 10px;} .expandable { text-decoration:underline; font-weight:bold; color:navy; cursor:hand; } Server Error in '/' Application. Timeout expired. The timeout period elapsed prior to completion of the operation or the server is not responding. Description: An unhandled exception occurred during the execution of the current web request. Please review the stack trace for more information about the error and where it originated in the code. Exception Details: System.Data.SqlClient.SqlException: Timeout expired. The timeout period elapsed prior to completion of the operation or the server is not responding. Source Error: An unhandled exception was generated during the execution of the current web request. Information regarding the origin and location of the exception can be identified using the exception stack trace below. Stack Trace: [Sq... Massey researchers induce cell death in leukemia... Under a Clinical Trials Agreement signed with CuraGen, the NCI is sponsoring several clinical trials investigating belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In order to better understand belinostat's anti-tumor activity and to provide supporting information for clinical trials, TopoTarget signed a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies with belinostat. CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody- drug conjugate and small molecule therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com. TopoTarget (CSE: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK and Germany, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer t... Jury Awards Newport News Woman $5.55 Million...
WTKR.COM YOUR NEWSCHANNEL 3 - Jury Awards Newport News Woman $5.55 Million
#COLUMN4 {
background-color: #FFFFFF;
}
.memberCenter {
font-family:Verdana,Arial;
font-size:10px;
color:#000000;
}
.memberCenter A {
font-family:Verdana,Arial;
font-size:9px;
color:#4D4D4D;
}
.memberCenter LI {
list-style-type: square;
}
FONT {
font-family: Verdana,Arial;
}
A {
font-family: Verdana,Arial;
}
FONT.a {
text-decoration:underline;
}
FONT.sectiontitle {
font-size:9px;
color:#333333;
}
.font2 { font-size:135%; }
.font2 FONT, .font2 TABLE { font-size:100%; }
.font3 { font-size:170%; }
.font3 FONT, .font3 TABLE { font-size:100%; }
A:link { text-decoration:none; }
A:visited { text-decoration:none; }
A:active { text-decoration:none; }
A:hover { text-decoration:underline; }
.wnUtilityBlock { text-align: center; }
.wnUtilityBlock TABLE { margin: 0 auto; }
.wnUtilityBlock TABLE TABLE { margin: 0; }
FONT.bn {
color:#FFFFFF;
font-family:Verdana,Arial;
font-size:10px;
text-decoration:underline;
}
FONT.bnl {
color:#FFFFFF;
font-family:Verdana,Arial;
font-size:10px;
text-decoration:none;
}
TD.ctdcrn {
padding-left:0px;
padding-right:0px;
}
A.ctdoff {
font-weight:700;
text-decoration:none;
}
DIV.ads {
margin: 5px;
}
IMG.video {
vertical-align: middle;
}
TEXTAREA.qform {
font-family:Verdana,Arial;
}
DIV.wrapper_wnsz_41 {
background-color: #F5F5F5;
border-color: #D1D1D1;
border-style: solid;
border-bottom-width: 0px;
border-left-width: 1px;
border-right-width: 1px;
border-top-width: 1px;
width: 980px... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news |